39 / 86
Preplanned OS Subgroups Analysis
1. Schöffski P, et al. Presented at ASCO 2015 Annual Meeting, Chicago IL, June 3-7, 2015:abstr LBA10502
2. Schöffski P, et al. Lancet. 2016 Apr 16;387(10028):1629-37
Histology
ADI
LMS
52/71
124/157
63/72
118/152
0.511 (0.346-0.753)
0.927 (0.714-1.203)
15.6
12.7
8.4
13
AJCC sarcoma tumor grade score
at the date of diagnosis
High
Intermediate
118/150
57/77
125/152
55/69
0.796 (0.607-1.042)
0.649 (0.439-0.961)
12.7
14.8
11.5
10.1
Baseline ECOG PS
0
1
2
76/111
97/114
3/3
72/90
97/121
12/13
0.579 (0.407-0.823)
1.107 (0.826-1.484)
3.000 (0.251-35.794)
19.9
9.4
1.1
13.1
10.1
3
Prior anticancer therapy type
Anthracycline
Gemcitabine
Ifosfamide
Taxane
Trabectedin
Targeted therapy
Other
174/225
101/129
108/141
87/109
80/108
23/29
66/83
177/219
111/138
115/137
92/114
98/116
19/26
70/90
0.770 (0.619-0.958)
0.803 (0.600-1.074)
0.701 (0.529-0.930)
0.835 (0.604-1.156)
0.643 (0.469-0.884)
1.067 (0.527-2.161)
0.902 (0.631-1.289)
13.5
13.2
14.7
11.3
13.3
11.3
11.3
11.3
11.8
11
11.6
10.7
13.1
12.2
Group/Subgroup
Eribulin Dacarbazine
—
EVENTS/n
—
Eribulin Dacarbazine
MEDIAN (mos)
HR (95% CI)
0.25
1
4
16
Favors Eribulin
Favors Dacarbazine
AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Oncology Group.